The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?
 
Katerina Mary Zakka
No Relationships to Disclose
 
Shayla Williamson
No Relationships to Disclose
 
Renjian Jiang
No Relationships to Disclose
 
Olatunji B. Alese
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Conjupro Biotherapeutics; Conjupro Biotherapeutics; Conjupro Biotherapeutics; Conjupro Biotherapeutics; Exelixis; Exelixis; Exelixis; Exelixis; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Acetylon Pharmaceuticals (Inst); Acetylon Pharmaceuticals (Inst); Acetylon Pharmaceuticals (Inst); Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Exelixis; Exelixis; Exelixis; Exelixis
 
Walid Labib Shaib
Research Funding - ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst)
 
Christina Wu
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lycera (Inst); Lycera (Inst); Lycera (Inst); Lycera (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Vaccinex (Inst); Vaccinex (Inst); Vaccinex (Inst); Vaccinex (Inst)
 
Madhusmita Behera
No Relationships to Disclose
 
Bassel F. El-Rayes
Honoraria - Bayer; Bayer; Bayer; Bayer; Lexicon; Lexicon; Lexicon; Lexicon; RTI Health Solutions; RTI Health Solutions; RTI Health Solutions; RTI Health Solutions
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; BTG; BTG; BTG; BTG; Loxo; Loxo; Loxo; Loxo; Merrimack; Merrimack; Merrimack; Merrimack; RTI Health Solutions; RTI Health Solutions; RTI Health Solutions; RTI Health Solutions
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lexicon; Lexicon; Lexicon; Lexicon
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Cleave Biosciences (Inst); Cleave Biosciences (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); ICON Clinical Research (Inst); ICON Clinical Research (Inst); ICON Clinical Research (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); PPD (Inst); PPD (Inst); PPD (Inst); PPD (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst)
Other Relationship - ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Exelixis; Exelixis; Exelixis; Exelixis
 
Mehmet Akce
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Polaris (Inst); Polaris (Inst); Polaris (Inst); Polaris (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst)